Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy
This study is currently recruiting participants.
Verified by Aultman Health Foundation, April 2008
Sponsored by: Aultman Health Foundation
Information provided by: Aultman Health Foundation
ClinicalTrials.gov Identifier: NCT00550290
  Purpose

This randomized prospective study will specifically investigate the efficacy of a 24 hour post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in preventing wound infection and wound breakdown following vulvectomy.


Condition Intervention
Wound Infection
Drug: Cefazolin (or Clindamycin in patients with allergy to cephalosporins or PCN)

MedlinePlus related topics: Antibiotics
Drug Information available for: Clindamycin Clindamycin hydrochloride Clindamycin palmitate Clindamycin Palmitate Hydrochloride Clindamycin phosphate Penicillins Cefazolin Cefazolin sodium Cefixime
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title: Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy

Further study details as provided by Aultman Health Foundation:

Primary Outcome Measures:
  • Febrile episodes, white blood cell counts, physical exam findings of vulva post-operatively [ Time Frame: First 2 weeks of post-operative course ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evidence of wound infection (fever, leukocytosis, or physical exam findings of infection such as induration, edema, erythema) [ Time Frame: Within the first 2 post-operative weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 160
Study Start Date: October 2007
Estimated Study Completion Date: April 2008
Estimated Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: No Intervention
2: Active Comparator
Patients receiving 24 hours of prophylactic antibiotics in the post-operative period following vulvectomy.
Drug: Cefazolin (or Clindamycin in patients with allergy to cephalosporins or PCN)
Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.

Detailed Description:

Infectious morbidity in gynecologic oncology has not been thoroughly investigated to date. Included in the literature are several studies that highlight substantial numbers of post-surgical infectious complications. Specifically among patients undergoing radical vulvectomy, the incidence of post-operative wound complication is as high as 58%. Surgery is the treatment of choice for vulvar cancer, but few studies establish protocols or management strategies to prevent the complications of post-operative wound infection and breakdown. This proposed randomized prospective study would specifically investigate the efficacy of a 24 hour post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in preventing wound infection and wound breakdown following vulvectomy. This same regimen has been described by a leader in the field of gynecology in his text - TeLinde's Operative Gynecology. This study will utilize two arms - one as the treatment arm utilizing 24 hours of prophylactic antibiotics and the other as control.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All female patients 18 years of age or older undergoing surgery for vulvar carcinoma (this includes female patients undergoing any form of vulvectomy - radical, vulvectomy without groin node dissection, and partial vulvectomy)
  • Disease State will not affect inclusion in the study. Women with previous surgery for vulvar carcinoma will be included as will those undergoing initial operation.
  • Number of subjects: 160

Exclusion Criteria:

  • Women simultaneously undergoing treatment for other forms of cancer
  • Women under the age of 18
  • Pregnant patients
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00550290

Contacts
Contact: William T Schnettler, MD 330-363-6214 wscnettler@aultman.com
Contact: Michael P Hopkins, MD 330-363-6214 mhopkins@aultman.com

Locations
United States, Ohio
Aultman Health Foundation Recruiting
Canton, Ohio, United States, 44710
Contact: William T Scnettler, MD     330-363-6214     wschnettler@aultman.com    
Contact: Michael P Hopkins, MD     330-363-6214     mhopkins@aultman.com    
Principal Investigator: William T Schnettler, MD            
Sponsors and Collaborators
Aultman Health Foundation
Investigators
Study Chair: Michael P Hopkins, MD Aultman Health Foundation
Principal Investigator: William T. Schnettler, MD Aultman Health Foundation
  More Information

Responsible Party: Aultman Health Foundation ( Michael Hopkins, MD )
Study ID Numbers: 2007.07.26.E2
Study First Received: October 25, 2007
Last Updated: April 14, 2008
ClinicalTrials.gov Identifier: NCT00550290  
Health Authority: United States: Institutional Review Board

Keywords provided by Aultman Health Foundation:
vulvectomy
wound infection
wound complication
prophylactic antibiotic
Post-operative wound complications following vulvectomy

Study placed in the following topic categories:
Cephalosporins
Clindamycin
Cefazolin
Clindamycin-2-phosphate
Cefixime
Wounds and Injuries
Disorders of Environmental Origin
Wound Infection

Additional relevant MeSH terms:
Protein Synthesis Inhibitors
Anti-Infective Agents
Anti-Bacterial Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Enzyme Inhibitors
Infection
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009